The patentability of human embryonic stem cells in Europe

Article Abstract:

The impact of the Rule 23d(c) of the European Patent Convention (EPC) on human embryonic stem (hES) cell patenting strategy in Europe is examined and the implications for the biotech industry are highlighted. Analysis of European hES cell patents has illustrated the way the dynamics of the regulatory environment are shaping current patenting practice.

Europe, Drugs, Patents & copyrights, Biotechnology industry, Biotechnology industries, Intellectual property, Embryonic stem cells

---

Banking on red blood cells

Article Abstract:

Banked blood is in great demand and continues to outpace the supply, especially in developing countries. A technology that permits for the first time the extensive expansion of CD34(super +) stem cells and their total conversion ex vivo into mature enucleated red blood cells is described.

Blood and Organ Banks, Health and allied services, not elsewhere classified, Blood Banks & Collection Centers, Methods, Erythrocytes, Red blood cells, Blood transfusion, Blood banks

---

FDA likely to further restrict erythropoietin use for cancer patients

Article Abstract:

The U.S. Food and Drug Administration (FDA) have argued to ban erythropoietin used in treating cancer patients in order to evaluate the safety and efficiency of the product.

Care and treatment, Usage, Cancer patients, United States. Food and Drug Administration, Erythropoietin

Similar abstracts:

• Abstracts: Unnerved by unreturned calls. Gourmet's articles editor seeks feature ideas from publicists. Full house at PCNY
• Abstracts: Chinese buildup not a direct threat to U.S.: Rand. Congress likely to trim DHS budget plan: House leader. Experts assess China threat: New weapons, third-largest military
• Abstracts: Return of the students. Would like to meet.... Leap into the
• Abstracts: Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Hot spot MRI emerges from the background
• Abstracts: Biotech takes aim at large anti-estrogen markets. Stem cell therapy or snake oil? Poorer nations turn to publicly developed GM crops

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.